BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35168417)

  • 1. Medulloblastoma: WHO 2021 and Beyond.
    Cotter JA; Hawkins C
    Pediatr Dev Pathol; 2022; 25(1):23-33. PubMed ID: 35168417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline.
    Pietsch T; Haberler C
    Clin Neuropathol; 2016; 35(6):344-352. PubMed ID: 27781424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medulloblastoma].
    Yamaguchi S; Fujimura M
    No Shinkei Geka; 2023 Sep; 51(5):858-866. PubMed ID: 37743337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
    Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
    J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Markers as Predictors for Response to Treatment and Possible Therapeutic Targets in Medulloblastoma.
    Pérez-Pineda PL; Ortiz-Butrón R; Pérez-De Marcos JC; Hernández-Regino LM; Zapata-Tarrés MM; Torres-Espíndola LM
    CNS Neurol Disord Drug Targets; 2023; 22(5):634-642. PubMed ID: 35579144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling pathway deregulation and molecular alterations across pediatric medulloblastomas.
    Lhermitte B; Blandin AF; Coca A; Guerin E; Durand A; Entz-Werlé N
    Neurochirurgie; 2021 Feb; 67(1):39-45. PubMed ID: 29776650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
    Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
    Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
    [No Abstract]   [Full Text] [Related]  

  • 9. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
    Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
    Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
    Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
    D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
    J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.
    Chinnam D; Saraswati A; Jogunoori S; Verma A; Kiran T; Salunke P; Gupta N; Kumar N; Madan R; Radotra BD; Gupta K
    Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):561-568. PubMed ID: 37471625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuropathology of medulloblastomas and other CNS embryonal tumors : Precision diagnostics through the integration of genetic markers].
    Pietsch T
    Pathologe; 2019 Mar; 40(2):140-147. PubMed ID: 30790012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
    Cambruzzi E
    Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medulloblastoma. Pathology].
    Siegfried A; Delisle MB
    Neurochirurgie; 2021 Feb; 67(1):28-38. PubMed ID: 29703584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are molecular subgroups of medulloblastomas really prognostic?
    Frappaz D; Faure-Conter C; Meyronet D; Levard-Bonneville A; Beuriat PA; Sunyach MP; Barritault M
    Curr Opin Neurol; 2018 Dec; 31(6):747-751. PubMed ID: 30300240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.
    Keil VC; Warmuth-Metz M; Reh C; Enkirch SJ; Reinert C; Beier D; Jones DTW; Pietsch T; Schild HH; Hattingen E; Hau P
    AJNR Am J Neuroradiol; 2017 Oct; 38(10):1892-1898. PubMed ID: 28798218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical staining of LEF-1 is a useful marker for distinguishing WNT-activated medulloblastomas.
    Wang D; Gong J; Zhang H; Liu Y; Sun N; Hao X; Mu K
    Diagn Pathol; 2022 Sep; 17(1):69. PubMed ID: 36096860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.